Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
151 hedge funds and large institutions have $578M invested in Array Biopharma Inc in 2015 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 48 increasing their positions, 45 reducing their positions, and 28 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 45
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 157 → 151 (-6)
11% less capital invested
Capital invested by funds: $653M → $578M (-$75M)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
44% less call options, than puts
Call options by funds: $6.85M | Put options by funds: $12.2M
Top Buyers
| 1 |
Millennium Management
New York
|
+$11.1M |
| 2 |
Renaissance Technologies
New York
|
+$10.4M |
| 3 |
VAM
Visium Asset Management
New York
|
+$9.08M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$4.86M |
| 5 |
TA
Teachers Advisors
New York
|
+$4.77M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.5M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$16.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$13.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$10.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.54M |
ARRY Hedge Fund Activity: Q4 2015 in Review
151 of the 3,811 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2015, worth a combined $578M — down 11% from $653M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ARRY and 23 opened new positions — a net loss of 5 holders — while 45 trimmed existing stakes and 48 added.
The largest buyer was Millennium Management, adding an estimated $11.1M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $23.5M sold.
- 151 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2015, down from 157 in Q3 2015.
- Funds reported $578M of Array Biopharma Inc stock for Q4 2015, down 11% quarter-over-quarter.
- 23 funds opened new Array Biopharma Inc positions in Q4 2015 and 28 closed out, a net change of -5 holders.
- The largest Array Biopharma Inc buyer in Q4 2015 was Millennium Management, an estimated $11.1M added.
- The largest Array Biopharma Inc seller in Q4 2015 was T. Rowe Price Associates, an estimated $23.5M sold.
Based on aggregated 13F filings for Q4 2015.